W
W. Winn Chatham
Researcher at University of Alabama at Birmingham
Publications - 98
Citations - 10333
W. Winn Chatham is an academic researcher from University of Alabama at Birmingham. The author has contributed to research in topics: Lupus erythematosus & Belimumab. The author has an hindex of 34, co-authored 91 publications receiving 9014 citations. Previous affiliations of W. Winn Chatham include University of Alabama & University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis
Jasvinder A. Singh,Daniel E. Furst,Aseem Bharat,Jeffrey R. Curtis,Arthur Kavanaugh,Joel M. Kremer,Larry W. Moreland,James O'Dell,Kevin L. Winthrop,Timothy Beukelman,S. Louis Bridges,W. Winn Chatham,Harold E. Paulus,Maria E. Suarez-Almazor,Claire Bombardier,Maxime Dougados,Dinesh Khanna,Charles M. King,Amye L. Leong,Eric L. Matteson,John T. Schousboe,Eileen Moynihan,Karen S. Kolba,Archana Jain,Elizabeth R. Volkmann,Harsh Agrawal,Sangmee Bae,Amy S. Mudano,Nivedita M. Patkar,Kenneth G. Saag +29 more
TL;DR: The 2012 ACR RA recommendations were developed by two expert panels: a non-voting working group and Core Expert Panel of clinicians and methodologists responsible for the selection of the relevant topic areas to be considered, the systematic literature review, and the evidence synthesis.
Journal ArticleDOI
American College of Rheumatology 2008 Recommendations for the Use of Nonbiologic and Biologic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis
Kenneth G. Saag,Gim Gee Teng,Nivedita M. Patkar,Jeremy Anuntiyo,Catherine Finney,Jeffrey R. Curtis,Harold E. Paulus,Amy S. Mudano,Maria Pisu,Mary Elkins-Melton,Ryan C. Outman,Jeroan J. Allison,Maria Suarez Almazor,S. Louis Bridges,W. Winn Chatham,Marc C. Hochberg,Catherine H. MacLean,Ted R. Mikuls,Larry W. Moreland,James O'Dell,Anthony M. Turkiewicz,Daniel E. Furst +21 more
TL;DR: Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology are intended to provide guidance for particular patterns of practice and not to dictate the care of a particular patient.
Journal ArticleDOI
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
Richard Furie,Michelle A. Petri,Omid Zamani,Ricard Cervera,Daniel J. Wallace,D. Tegzova,Jorge Sanchez-Guerrero,Andreas Schwarting,Joan T. Merrill,W. Winn Chatham,William Stohl,Ellen M. Ginzler,Douglas R. Hough,Z. John Zhong,William W. Freimuth,Ronald F van Vollenhoven +15 more
TL;DR: Belimumab plus standard therapy significantly improved SRI response rate, reduced SLE disease activity and severe flares, and was generally well tolerated in SLE.
Journal ArticleDOI
Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial.
Bita Shakoory,Joseph A. Carcillo,W. Winn Chatham,Richard L. Amdur,Huaqing Zhao,Charles A. Dinarello,Randall Q. Cron,Steven M. Opal +7 more
TL;DR: In this subgroup analysis, interleukin-1 receptor blockade was associated with significant improvement in survival of patients with sepsis and concurrent hepatobiliary dysfunction/disseminated intravascular coagulation.
Journal ArticleDOI
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Belimumab in Patients With Active Systemic Lupus Erythematosus
Daniel J. Wallace,William Stohl,Richard Furie,Jeffrey R. Lisse,James D. McKay,Joan T. Merrill,Michelle A. Petri,Ellen M. Ginzler,W. Winn Chatham,W. Joseph McCune,Vivian Fernandez,Marc Chevrier,Z. John Zhong,William W. Freimuth +13 more
TL;DR: Belimumab was biologically active and well tolerated and the effect of belimumab on the reduction of SLE disease activity or flares was not significant, however, serologically active SLE patients responded significantly better to belicumab therapy plus SOC than to SOC alone.